Key Primary Resverlogix Objective Obtained

San Diego, California and Calgary, Canada (ots/PRNewswire) -

- Findings Demonstrate Clear Trends of Proof of Principle of
Reverse Cholesterol Transport in Human Volunteers

SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ --

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX)
announced today that it has completed the planned exploratory
efficacy analysis of the data from the Phase I, 7 day RVX-208
treatment subjects. Analysis from two independent and external
laboratories of blinded serum samples showed consistent improvements
of key biomarkers for the RCT (reverse cholesterol transport)
pathway.

"Analysis from 24 healthy volunteers in the 7 day RVX-208 trial
showed statistically significant improvements over placebo in 3 of
the 4 key variables assessed," stated Donald J. McCaffrey, President
& CEO of Resverlogix. A fourth variable also showed positive trending
but was not validated as statistically significant. McCaffrey
emphasized, "All other lipid parameters behaved as anticipated. As
efficacy is the one of the goals of our upcoming 28 day Phase 1b/2a
trial we are very pleased to see the primary indicators behaving as
they did. We were especially pleased to see the increases in pre-beta
HDL of in excess of 30%, cholesterol efflux above 10%, serum ApoA-I
above 10%, and HDL-C above 10% (not statistically significant) versus
placebo. This follows a very similar improvement pattern as
previously demonstrated by Resverlogix in the African Green Monkey
studies. Crucial to these findings is the rapid onset of action in
this 7 day trial, with the serum ApoA-I increases surpassing the
previous 8% five week (35 day) average benchmark totals displayed by
Pfizer's previous ApoA-I Milano recombinant protein studies."

McCaffrey continued, "What has been truly unique about RVX-208
versus other small molecule HDL/ApoA-I programs is that RVX-208
facilitates endogenous ApoA-I production. Resverlogix now has a
commanding lead in the development of atherosclerosis therapeutics.
To our knowledge no other small molecules, whether it is the statins,
other HDL drugs or lipid modifying programs have demonstrated HDL
functionality and RCT."

RCT is a pathway by which accumulated cholesterol is transported
from the arterial wall to the liver for excretion, thus preventing
atherosclerosis. Major constituents of RCT include acceptors such as
high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A
critical part of RCT is cholesterol efflux, in which accumulated
cholesterol is removed from macrophages.

Resverlogix will be presenting at the BIO Business Forum held in
San Diego, California on Thursday June 19, 2008 at 1:15pm PDT in Room
4.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com
Website: http://www.resverlogix.com/

SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ --

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax:
+1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com .